Peter Parker

Mr. Parker is Managing General Partner of BioInnovation Capital. Previously, Peter Parker was a General Partner at Ampersand Capital Partners, Wellesley MA, where he co-led the firm’s Life Sciences activities.

Mr. Parker has played a major role in the greater Boston/Cambridge life sciences start-up community. At MassChallenge, he was the healthcare/life sciences ‘Champion’ for that Boston accelerator for five years. He is a co-founder of BioInnovation Capital, Cambridge BioLabs and the BioLabs network, and is a member of several Angel investing groups. Together with Johannes Fruehauf he launched LabCentral, Inc., a major addition to the life sciences start-up ecosystem on the East coast.

From 2006–2010 he was President and CEO of Cequent Pharmaceuticals

sold to Marina Biotech). He has served as a director of numerous companies, including ACLARA Biosciences, Tomah Products, VITEX, Magellan Biosciences, Dynex, Castlewood Surgical and Pentose Pharmaceuticals and as Chairman of Alexis, NOVEX, CoPharma, Huntington Laboratories, Protein Ingredient Technologies, Cyclis Pharmaceuticals, Nanodyne, Panacos Pharmaceuticals, AC Tech, BioEssences and TekCel.

Peter Parker holds BS and MS degrees from Columbia University.